Evidence map›Paper›PMID 39851961›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Perspectives of Women with Breast Cancer and Healthcare Providers Participating in an Adherence-Enhancing Program for Adjuvant Endocrine Therapy: A Qualitative Study.

Véronique Turcotte, Laurence Guillaumie, Martine Lemay, Anne Dionne, Julie Lemieux, Angéline Labbé, Carolyn Gotay, Line Guénette, Sophie Lauzier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Véronique TurcottePopulation Health and Optimal Health Practices Axis, CHU de Québec-Université Laval Research Center, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1S 4L8, Canada.
Laurence GuillaumiePopulation Health and Optimal Health Practices Axis, CHU de Québec-Université Laval Research Center, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1S 4L8, Canada.
Martine LemayCentre des Maladies du Sein, CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1S 4L8, Canada.
Anne DionneCentre des Maladies du Sein, CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1S 4L8, Canada.
Julie LemieuxCentre des Maladies du Sein, CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1S 4L8, Canada.
Angéline LabbéCentre Interdisciplinaire De Recherche en Réadaptation Et Intégration Sociale (CIRRIS), 525 Boulevard Wilfrid-Hamel, Québec, QC G1M 2S8, Canada.
Carolyn GotaySchool of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, BC V6T 1Z3, Canada.
Line GuénettePopulation Health and Optimal Health Practices Axis, CHU de Québec-Université Laval Research Center, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1S 4L8, Canada.ORCID 0000-0001-9769-7550
Sophie LauzierPopulation Health and Optimal Health Practices Axis, CHU de Québec-Université Laval Research Center, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Québec, QC G1S 4L8, Canada.

Funding

Canadian Institutes of Health Research (CIHR) 367503Fondation du CHU de Québec-Université Laval 3167 and 4024Unité Soutien SSA du Québec 313085
6 · The paper itself

Abstract

backgroundAdjuvant endocrine therapy (AET) is prescribed for 5-10 years to women with hormone-sensitive breast cancer to prevent recurrence. However, a significant proportion of women do not adhere to AET. We developed SOIE, a one-year program designed to enhance the AET experience and adherence. SOIE was pilot-tested in a mixed-methods randomized controlled trial. This report presents the experience of women and healthcare providers (HCPs) with SOIE.

methodsA descriptive qualitative study using semi-structured interviews and thematic analysis was conducted with 20 women and 7 HCPs who participated in the program.

resultsMost women and HCPs reported high satisfaction with the program. Women felt it addressed their need for information and strategies to manage side effects. They felt supported and developed a more positive attitude toward AET, which contributed to their intention to pursue AET. They perceived that the program helped them navigate the AET experience and reduced their stress or fear regarding AET. HCPs corroborated these benefits.

conclusionsFindings suggest that SOIE can enhance the experience and motivation to pursue the AET treatment by meeting important needs for information, side-effects management, and psycho-emotional support. Programs like SOIE can have benefits beyond adherence by improving patients' well-being during this crucial long-term treatment.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsHealth PersonnelMedication AdherenceAdultAgedChemotherapy, AdjuvantFemaleHumansMiddle AgedQualitative ResearchAntineoplastic Agents, Hormonalaromatase inhibitorsbreast neoplasmsmedication adherencepilot studyqualitative researchrandomized clinical trialsurvivorshiptamoxifen

Identifiers

PMID39851961
PMCPMC11764025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.